{"title":"Cervical cancer screening in immunosuppressed women: Is pap smear enough?","authors":"Swati Agrawal, Prerna Tayal, Reena Yadav, Smita Singh","doi":"10.4103/jclgtp.jclgtp_14_23","DOIUrl":null,"url":null,"abstract":"Aim: The present study aims to compare Pap test (liquid-based cytology [LBC]) and colposcopy for the detection of preinvasive lesions of the cervix in iatrogenically immunosuppressed women. Methodology: This study was a cross-sectional, observational study conducted on 75 iatrogenically immunosuppressed women in the age group of 25–50 years. The recruited women were screened by Pap test (LBC) and colposcopy at the same visit, and SWEDE score was calculated. Colposcopy-guided biopsies were taken from abnormal areas if the SWEDE score was >5. Results of histopathology were then correlated with colposcopic findings and cytology report. Results: The percentage of women with abnormal Pap test was 6.7% (5 out of 75 women), and the percentage of women with abnormal colposcopy was 9.3% (7 out of 75 women). The percentage of women with histopathology confirmed preinvasive and invasive lesions of the cervix was calculated to be 6.7% (5 out of 75 women). Pap smear (LBC) and colposcopy were found to have almost perfect agreement by the kappa coefficient (0.819) in the detection of preinvasive lesions of the cervix and cervical cancer for iatrogenically immunosuppressed women. Conclusion: Considering the skill and setup requirements associated with colposcopy and almost perfect agreement with the Pap test, the authors conclude that Pap test should continue to be used as the primary screening modality for screening in immunosuppressed women as well. The frequency of screening may be annual rather than 3 yearly in these women to pick up any low-grade lesions which might have been missed by the Pap test.","PeriodicalId":476164,"journal":{"name":"Journal of Colposcopy and Lower Genital Tract Pathology","volume":"25 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Colposcopy and Lower Genital Tract Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jclgtp.jclgtp_14_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: The present study aims to compare Pap test (liquid-based cytology [LBC]) and colposcopy for the detection of preinvasive lesions of the cervix in iatrogenically immunosuppressed women. Methodology: This study was a cross-sectional, observational study conducted on 75 iatrogenically immunosuppressed women in the age group of 25–50 years. The recruited women were screened by Pap test (LBC) and colposcopy at the same visit, and SWEDE score was calculated. Colposcopy-guided biopsies were taken from abnormal areas if the SWEDE score was >5. Results of histopathology were then correlated with colposcopic findings and cytology report. Results: The percentage of women with abnormal Pap test was 6.7% (5 out of 75 women), and the percentage of women with abnormal colposcopy was 9.3% (7 out of 75 women). The percentage of women with histopathology confirmed preinvasive and invasive lesions of the cervix was calculated to be 6.7% (5 out of 75 women). Pap smear (LBC) and colposcopy were found to have almost perfect agreement by the kappa coefficient (0.819) in the detection of preinvasive lesions of the cervix and cervical cancer for iatrogenically immunosuppressed women. Conclusion: Considering the skill and setup requirements associated with colposcopy and almost perfect agreement with the Pap test, the authors conclude that Pap test should continue to be used as the primary screening modality for screening in immunosuppressed women as well. The frequency of screening may be annual rather than 3 yearly in these women to pick up any low-grade lesions which might have been missed by the Pap test.